GILEAD SCIENCES, INC. is 31.1x more valuable than CG Oncology, Inc. by market capitalization ($150.83 B vs $4.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CGON | GILD |
|---|---|---|
| Market cap | $4.84 B | $150.83 B |
| US-listed rank | #1405 | #99 |
| Revenue (latest FY) | $4.04M | $29.44B |
| Net income (latest FY) | -$161.00M | $8.51B |
| Net margin | -3985.1% | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 189 | 981 |
GILEAD SCIENCES, INC. is 31.1x more valuable than CG Oncology, Inc. by market capitalization ($150.83 B vs $4.84 B).
In their latest fiscal years, CG Oncology, Inc. reported $4.04M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: CG Oncology, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.